Expression of EPK in Recurrent Miscarriage

MAP Kinase Signaling Pathways Through ERK and p-ERK Protein in Human Placenta of Women With Recurrent Miscarriage

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02694367

Acronym

EPK-RM

Enrollment

Registered

2016-02-29

Start date

2015-01-31

Completion date

2016-01-31

Last updated

2016-02-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Miscarriage

Keywords

genetic basis

Brief summary

The present study is based on hypotheses that some as yet unknown genetic factors may result in recurrent miscarriage (RM). Consequently, the main aim of this study was to gain new information about the underlying genetic causes of RM in the Egyptian population and to investigate the expression of ERK and p-ERK protein in human placenta and their corresponding tissue, to assess the significance of MAPK signal pathway in progression of recurrent miscarriage and PI3K-Akt Pathway.

Interventions

OTHERInvestigate the MAP kinase signaling pathways through ERK and p-ERK proteins

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

1. Gestational age less than 12 weeks. 2. no uterine abnormalities (examined by ultrasonography or hysterosonogram) 3. previous history of RM, defined as two or more consecutive miscarriages

Exclusion criteria

1. Gestational age 12 weeks or more. 2. Endocrine etiology like (thyroid dysfunction, and uncontrolled diabetes mellitus). 3. Antiphospholipid syndrome, inherited thrombophilias, alloimmune causes. 4. Uterine anatomic anomalies

Design outcomes

Primary

Measure	Time frame
The levels of ERK and AKT in placenta	48 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026